Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine extended release - Valerio Therapeutics/Monopar Therapeutics

Next Previous
Search
Drug Profile

Clonidine extended release - Valerio Therapeutics/Monopar Therapeutics

Alternative Names: BA-028; Clonidine extended-release - BioAlliance Pharma; Clonidine HCl MBT; Clonidine HCl Mucoadhesive Buccal Tablet; Clonidine Lauriad; Clonidine MBT; Clonidine XR; Validive

Latest Information Update: 08 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAlliance Pharma
  • Developer Monopar Therapeutics; Valerio Therapeutics
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Behavioural disorder therapies; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 27 Mar 2023 Monopar Therapeutics terminates its licence with Onxeo (now Valerio Therapeutics) for Validive (Monopar Therapeutics - SEC file 2024)
  • 27 Mar 2023 Discontinued - Phase-II/III for Stomatitis (Prevention, Chemotherapy-induced) in Puerto Rico (Buccal)
  • 27 Mar 2023 Monopar Therapeutics terminates phase II/III trials in Stomatitis (Prevention, Chemotherapy-induced) in France, Germany, Puerto Rico, Spain, United States and Poland due to not meeting the pre-specified efficacy threshold(Buccal) (NCT04648020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top